Essex Investment Management Co. LLC raised its position in Opko Health Inc. (NYSE:OPK) by 12.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 377,496 shares of the company’s stock after buying an additional 41,607 shares during the period. Essex Investment Management Co. LLC’s holdings in Opko Health were worth $3,526,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the company. Financial Architects Inc boosted its position in shares of Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock worth $102,000 after buying an additional 1,940 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Opko Health during the first quarter worth $141,000. Capstone Asset Management Co. boosted its position in shares of Opko Health by 16.4% in the second quarter. Capstone Asset Management Co. now owns 15,696 shares of the company’s stock worth $147,000 after buying an additional 2,210 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Opko Health during the second quarter worth $159,000. Finally, BlueMountain Capital Management LLC purchased a new position in shares of Opko Health during the first quarter worth $183,000.
Shares of Opko Health Inc. (NYSE:OPK) traded down 2.86% during midday trading on Wednesday, reaching $10.87. 3,833,982 shares of the company’s stock traded hands. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The stock has a market cap of $5.98 billion and a P/E ratio of 45.48. The stock has a 50 day moving average of $9.93 and a 200-day moving average of $10.11.
Opko Health (NYSE:OPK) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to analyst estimates of $324.11 million. During the same quarter last year, the company earned ($0.09) earnings per share. The company’s quarterly revenue was up 742.2% compared to the same quarter last year. On average, equities research analysts forecast that Opko Health Inc. will post ($0.05) EPS for the current fiscal year.
OPK has been the topic of several research reports. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Standpoint Research initiated coverage on shares of Opko Health in a research report on Friday, June 3rd. They issued a “buy” rating and a $16.00 price objective on the stock. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a research report on Thursday, June 16th. Jefferies Group reaffirmed a “hold” rating and issued a $10.00 price objective (down from $11.00) on shares of Opko Health in a research report on Friday, June 17th. Finally, Deutsche Bank AG cut their price objective on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research report on Thursday, June 16th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and a consensus target price of $13.20.
In other news, CEO Phillip Md Et Al Frost acquired 48,400 shares of the firm’s stock in a transaction dated Thursday, August 25th. The stock was bought at an average cost of $9.06 per share, for a total transaction of $438,504.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $27,804,696.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NYSE:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.